Omnes et al. in €4m series-A round for Horama

Go Capital invested via its Go Capital Amorçage fund. Sham Innovation, an investment vehicle created by insurer Sham in 2014 to invest in health companies in partnership with Turenne Capital, was advised by the latter.

The raised funds will be used to bolster the research team and support the development of two products – HORA-PDE6B, planning to enroll its first patient in Q1 2017, and HORA-RLPB1, currently at pre-clinical stage.

Christine Placet, previously at biotechnology company Trophos, was recently made CEO of Horama. Several recruitments will be made to build a team of specialised drug development experts working by her side.

Company
Horama is a biotechnology company dedicated to the development of innovative gene therapy products for the treatment of rare ophthalmic pathologies, such as retinal dystrophies. The company's portfolio includes a clinical-stage product and two products that will enter clinical stage in the coming months.

Horama was founded in 2014 in Paris by Denis Cayet, on the initiative of academic researchers, who carried out the first gene therapy trial for ophthalmology in 2011.

People
Omnes Capital – Bruno Montanari (partner).
Turenne Capital – Mounia Chaoui (partner).
Go Capital – Leila Nicolas (investment manager).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Omnes Capital
• Turenne Capital Partenaires
• Venture